

Financial Highlights

REVENUE

\$8.3m

(unaudited)

Driven by record recreational cannabis revenue of \$6.2 million

and pharmaceutical cannabis revenue of 2.1 million.

CASH FLOW

Positive Operating cash flow of

\$304,000

supported by cost-saving initiatives

■ FY25 GUIDANCE REFINED & REAFFIRMED

Revenue of

\$50m - \$57m

EBITDA between

\$4m - \$5.5m



Key Operational Achievements

OCost Reduction Program


On track to deliver \$4.0 million in annualised savings.

MyAccess Clinics Business Divestment

 Sold for \$1.0 million, cutting \$1.5 million in annual costs and improving focus on core business.

US Expansion

· New emulsion lab in Florida, joint venture with Flora Growth for cannabisinfused beverages.





r personal use only

Peak Canada - Recreational Cannabis Growth

RECORD
QUARTERLY
REVENUE

\$6.2m

✓ CASH RECEIPTS

\$5.2m


Cannabis Beverage Production


 Record demand aligns with improved production efficiencies. Growth is set to accelerate as Peak optimises operations to meet rising demand for its manufacturing services.

Product Diversification

- Broad capabilities across multiple product lines:
 - Vapes: Capacity for 8,000 units/day, meeting demand with fast delivery.
 - Topicals, Extraction & Packaging:
 Targeting wellness market growth and supporting diverse client needs.

Capacity vs Utilisation









personal use offiy

Peak USA - Expansion and Market Positioning

US CANNABIS BEVERAGE MARKET GROWTH

Projected market growth at

54.3% CAGC

targeting

\$19.06b

By 2028*.

Production & Distribution Expansion

• Establishment of an emulsion lab in Florida for THC infusion consistency.

Product Launch with Flora Growth

- **Melo Seltzers:** Flavours include Wild Berries, Grapefruit, and Strawberry (5mg THC).
- Cloud Cola: Flavours include Vintage Cola, Root Beer, and Orange Creamsicle (10mg THC).

Customer Expansion

Ongoing discussions with new US customers to extend market reach.





Althea - Pharmaceutical Cannabis Performance

QUARTERLY REVENUE

\$2.1m

CASH RECEIPTS

\$2.3m

In cash receipts

Supply Chain Recovery

• Transition to new suppliers completed, with improved pricing and reliable stock flow expected to boost gross margins.

Revenue Recovery and Growth

• Full product availability to resume by November 2024, positioning Althea to regain previous record levels (\$4.9 million in quarterly receipts) and drive market share expansion.

Strategic Focus

 Leveraging enhanced supplier agreements for better margins and consistent product availability, with plans to expand offerings across high-growth therapeutic areas.



Strategic Initiatives

COST REDUCTION SUCCESS

Annualised \$4.0 million in savings from restructuring and operational efficiencies.

MANAGEMENT ALIGNMENT

25% cash salary reduction for Directors, CEO and CFO, converting to performance rights (for AGM approval).

■ DIVESTMENT FOCUS

Sale of MyAccess Clinics business for \$1.0 million, reducing \$1.5 million in annual costs and sharpening focus on core segments.

GOVERNANCE STRENGTHENING

Search for FMCG experienced director to guide North American growth and support strategic objectives.



Focus on Shareholder Value

Financial Optimisation

Positive cash flow from cost management, divestitures, and efficient capital allocation.

Refined and Reaffirmed FY25 Guidance

• Revenue of between \$50 to 57 million with positive EBITDA of \$4 to 5.5 million, with the financial results expected to be more pronounced in the second half of the fiscal year.

Asset and Structure Review

Ongoing evaluation to align assets with growth objectives and optimise shareholder returns.

CEO Vision

• Strong financial base, unique cannabis beverages, and targeted growth initiatives build a defensible moat for long-term value creation.



Legal Disclaimer

Althea Group Holdings Limited ACN 626 966 943 (Company) has prepared this presentation (**Presentation**) dated 31 October 2024 to provide current and prospective investors in the Company with an update in relation to the Company, its subsidiaries and their activities. The information in this Presentation discusses the Company's operations and product range. It is not intended as a promotion of the Company's products.

This Presentation contains summary information about the Company, its subsidiaries and their activities which is current as at the date of this Presentation. The information in this Presentation is of a general nature and does not purport to be complete nor does it contain all the information which a prospective investor may require in evaluating a possible investment in the Company or that would be required in a prospectus or product disclosure statement prepared in accordance with the requirements of the Corporations Act 2001 (Cth).

This Presentation has not been and will not be filed with or approved by any regulatory authority in Australia, including the Australian Securities and Investments Commission (ASIC), or any other jurisdiction. The historical information in this Presentation is, or is based upon, information that has been lodged with the Australian Securities Exchange (ASX) and released on the ASX Market Announcements Platform. This Presentation should be read in conjunction with the Company's other periodic and continuous disclosure announcements which are available at www.asx.com.au (Company Code: AGH) or altheagroupholdings.com.



Contact us

Althea Group Holdings Ltd

Joshua Fegan

CEO & Managing Director

E: info@altheagroupholdings.com



